NA-Selank

What is Selank?

Selank (known chemically as TP-7 or Heptapeptide Selank) is a synthetic, regulatory heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Derived from the naturally occurring immunomodulatory tetrapeptide tuftsin, Selank incorporates a C-terminal Pro-Gly-Pro sequence to significantly enhance its metabolic stability and biological half-life. Researchers investigate this compound for its unique, non-sedating anxiolytic properties, neuroprotective capabilities, immune-modulating effects, and ability to enhance memory consolidation and cognitive flexibility under stress.

For laboratory and in vitro evaluation, researchers often choose to buy Selank in high-purity lyophilized or nasal spray reference formats. Reconstituted solutions can be securely prepared using sterile laboratory buffers or a specialized reconstitution solution to preserve peptide stability and prevent degradation during experimental protocols.

Chemical and Molecular Data

What are the Mechanisms of Action?

The biochemical pathways and cellular targets of Selank include:

• Enkephalin Degradation Inhibition: Research demonstrates that Selank competitively inhibits peptidases responsible for degrading endogenous enkephalins (such as carboxypeptidase N and enkephalinase). By extending the biological lifespan of naturally circulating enkephalins, Selank produces robust anxiolytic and stress-mitigating effects without inducing sedation or motor impairment.
• GABAergic & Monoaminergic Modulation: In addition to opioid peptide preservation, Selank allosterically modulates GABA_A receptor complexes, increasing receptor affinity for GABA. It also regulates central monoamine metabolism, altering serotonin breakdown and norepinephrine turnover rates in the hippocampus and frontal cortex.
• BDNF Upregulation & Immune Balancing: Studies indicate that Selank rapidly stimulates the gene expression of Brain-Derived Neurotrophic Factor (BDNF) and its receptor TrkB in hippocampal neurons, driving neuroplasticity. Furthermore, retaining its parent tuftsin lineage, it modulates inflammatory cytokines such as Interleukin-6 (IL-6) to maintain neuro-immune homeostasis.

What are the Clinical & Preclinical Trials on Selank?

When evaluating research efficacy and published experimental literature for Selank:

• Generalized Anxiety Disorder (GAD) Clinical Trials: Human clinical trials conducted in Europe evaluated Selank in patients with generalized anxiety disorder and neurasthenia. Results confirmed that Selank exhibited anxiolytic efficacy comparable to low-dose traditional benzodiazepines (such as medazepam), but completely lacked side effects like daytime drowsiness, muscle relaxation, cognitive impairment, dependence, or withdrawal symptoms.
• Neurotrophic Signaling & Memory Retention: Preclinical investigations detailed in PubMed (PMID: 18577961) analyzed gene expression alterations in rat hippocampal tissues following Selank administration. The data confirmed a rapid, multi-fold upregulation of BDNF mRNA expression, which directly correlated with enhanced spatial memory acquisition and resistance to stress-induced cognitive impairment.
• Immunomodulatory & Cytokine Regulation Assays: In vitro and in vivo immunological studies confirm that Selank suppresses elevated pro-inflammatory cytokine expression during acute systemic inflammation, highlighting its multi-target adaptability across neuro-endocrine and immune axes.

How does Selank compare to other compounds?

To evaluate neuro-pathway specificity, anxiolytic vs. stimulant profiles, and delivery mechanics, researchers compare Selank against structural analogs, central nervous system mineral transporters, and fast-acting acute cognitive matrices: